Premium
The penetration and distribution of topical atropine in animal ocular tissues
Author(s) -
Wang Louis Zizhao,
Syn Nicholas,
Li Shiya,
Barathi Veluchamy Amutha,
Tong Louis,
Neo Jason,
Beuerman Roger W.,
Zhou Lei
Publication year - 2019
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/aos.13889
Subject(s) - atropine , sclera , chemistry , cornea , conjunctiva , ciliary body , ophthalmology , pharmacokinetics , medicine , pharmacology , anesthesia , pathology
Purpose To conduct a multi‐tissue investigation on the penetration and distribution of topical atropine in myopia treatment, and determine if atropine is detectable in the untreated contralateral eye after uniocular instillation. Methods Nine mature New Zealand white rabbits were evenly divided into three groups. Each group was killed at 5, 24 and 72 hr, respectively, following uniocular instillation of 0.05 ml of 1% atropine. Tissues were sampled after enucleation: conjunctiva, sclera, cornea, iris, ciliary body, lens, retina, aqueous, and vitreous humors. The assay for atropine was performed using liquid chromatography‐mass spectrometry ( LC ‐ MS ), and molecular tissue distribution was illustrated using matrix‐assisted laser desorption ionization‐imaging mass spectrometry ( MALDI ‐ IMS ) via an independent experiment on murine eyes. Results At 5 hr, the highest (mean ± SEM) concentration of atropine was detected in the conjunctiva (19.05 ± 5.57 ng/mg, p < 0.05) with a concentration gradient established anteriorly to posteriorly, as supported by MALDI ‐ IMS . At 24 hr, preferential binding of atropine to posterior ocular tissues occurred, demonstrating a reversal of the initial concentration gradient. Atropine has good ocular bioavailability with concentrations of two magnitudes higher than its binding affinity in most tissues at 3 days. Crossing‐over of atropine to the untreated eye occurred within 5 hr post‐administration. Conclusion Both transcorneal and transconjunctival‐scleral routes are key in atropine absorption. Posterior ocular tissues could be important sites of action by atropine in myopic reduction. In uniocular atropine trials, cross‐over effects on the placebo eye should be adjusted to enhance results reliability. Combining the use of LC ‐ MS and MALDI ‐ IMS can be a viable approach in the study of the ocular pharmacokinetics of atropine.